At present, there are many LSD1/KDM1A inhibitors under clinical trial as a promising future cancer therapy with the majority of these being targeted against small-cell lung cancer (SCLC) and acute myeloid leukemia (AML) [103,104]. This evidence concerns the gene KDM1A and cancer.